Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries

Fig. 3

Cost-effectiveness analysis of three interventions to prevent RSV prophylaxis. The optimal strategy in terms of cost-effectiveness for each country and for a range of WTP values (0–30,000 USD per DALY averted) is indicated by the colours (the current strategy is no intervention). The size of the markers indicates how certain we are about that strategy being optimal. Countries are ranked by RSV incidence rate (ordered from high to low on the left Y-axis [incidence per 1000 person-year in brackets]) and stratified by income group (LIC or LMIC, on the right Y-axis)

Back to article page